Analysts at Deutsche Bank expect the Incremental growth in higher-margin revenues and the breadth of its supply chain to help "deftly navigate" incremental tariffs and reinvest in growth.
Jonah Cheng’s liquidation followed fears about delays in GB200 racks, inventory risks, a lack of upward revisions to earnings forecasts, competition from custom-designed chips, and uncertainty around spending by cloud computing companies.
Morgan Stanley’s James Faucette expects the company to raise the bottom end of its 2025 revenue guidance by 100 basis points, layering in longer-duration managed services contracts.
The National Labor Relations Board has written to the e-commerce giant to reinstate fired workers and ensure union supporters receive the raises, bonuses, and promotions.
Microsoft enhanced its European cloud offerings with advanced data control, sovereignty, and privacy tools, ensuring local data processing, stricter access oversight, and customer-managed encryption.
The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors.
The company stated that no safety signals were observed in the study comparing the efficacy and safety of Venetoclax in combination with Azacitidine compared to Azacitidine and placebo in the treatment of newly diagnosed, higher-risk MDS.
Sonim’s Special Committee, tasked with overseeing strategic alternatives, acknowledged the proposal but noted that it lacks the information needed to properly assess the offer.
The arrangement will offer exclusive access to 80 million U.S. CTV households via Amazon DSP, enabling advertisers to improve reach, targeting accuracy, and reduce ad repetition significantly.
The lingerie brand is already fighting to fend off a challenge from key shareholder BBRC International, which is blaming the company's board for poor performance.
In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said.
Investors are growing cautious about the timeline and payoff of Adobe’s AI initiatives, despite the company beating Q2 estimates and raising its full-year revenue forecast.
